Search Results - varghese+john

11 Results

Sort By:

2021-241: Enhancers of Brain Gamma Oscillations for Treatment of Neurological Disorders

SUMMARY: UCLA researchers in the Department of Neurology have developed a novel small molecule to improve native gamma oscillations as a treatment for cognitive decline in various neurological disorders. BACKGROUND: Neural circuits are facilitated by brain oscillations or rhythmic electric activity at distinct frequencies. These frequency variations...

Published: 9/5/2023 | Inventor(s): Varghese John, Istvan Mody, Jesus Campagna, Barbara Jagodzinska, Xiaofei Wei

Keywords(s):

Category(s): Therapeutics > CNS and Neurology, Therapeutics > Psychiatry And Mental Health

2022-177: DRUG COMBINATION TO INHIBIT BOTH MPRO AND PLPRO PROTEASES OF SARS-COV-2

SUMMARY: UCLA researchers in the Department of Neurology have developed a novel small-molecule protease inhibitor cocktail to robustly suppress COVID-19 infection. INTRODUCTION: COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Despite the development of vaccines, COVID-19 was the third-leading cause of death in the U.S. in 2021,...

Published: 9/5/2023 | Inventor(s): Varghese John, Robert Damoiseaux, Melody (Man Hing) Li

Keywords(s):

Category(s): Therapeutics, Therapeutics > Infectious Diseases, Therapeutics > Infectious Diseases > COVID

2020-832: Novel Compounds Targeting APOE4 That Enhance Brain SIRT1 Levels and Target Novel Mechanism of Action

Researchers at UCLA's Drug Discovery Lab and Department of Chemistry have developed new chemical entity (NCE) analogs of A03, which together form a new class of compounds that target apolipoprotein E4 (ApoE4)-mediated deficits in the tau deacetylase enzyme, sirtuin 1 (SirT1). These NCEs provide an opportunity for novel therapeutic development in Alzheimer's...

Published: 9/5/2023 | Inventor(s): Varghese John, Jesus Campagna, Michael Jung

Keywords(s): Brain

Category(s): Therapeutics

2020-408: sAPPalpha Targeted Therapeutics for Alzheimer’s Disease

UCLA researchers from the Department of Neurology have developed a novel application of two compounds that target the upstream formation of toxic amyloid-beta oligomers for the effective treatment of Alzheimer’s disease. BACKGROUND: Alzheimer’s Disease (AD) is the most common age-related neurodegenerative disorder currently affecting ~6...

Published: 7/19/2023 | Inventor(s): Varghese John, Sujyoti Chandra

Keywords(s): Chemical, Cns, Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > CNS and Neurology

2018-200 AMYLOID PRECURSOR PROTEIN-SELECTIVE BACE INHIBITORS (ASBIS) FOR ALZHEIMER’S DISEASE

Amyloid Precursor Protein-Selective BACE Inhibitors for Alzheimer’s DiseaseSUMMARYUCLA researchers in the Department of Neurology have invented novel Alzheimer’s disease (AD) therapeutics that are selective for BACE1 inhibition and cleavage of the amyloid precursor protein (APP) substrate.BACKGROUNDAlzheimer’s disease is characterized...

Published: 7/19/2023 | Inventor(s): Barbara Jagodzinska, Varghese John, Patricia Spilman, Jesus Campagna

Keywords(s): Cns, Life Science Research Tools, Medical Devices and Materials, Targets And Assays, Therapeutics & Vaccines

Category(s): Life Science Research Tools, Diagnostic Markers > Targets And Assays, Medical Devices, Therapeutics, Therapeutics > CNS and Neurology

2019-231: Radiotracer for Synaptic Imaging

UCLA researchers in the Department of Neurology have synthesized a novel radiotracer that selectively identifies functional synapses for monitoring of synaptic loss in Alzheimer’s patients. BACKGROUND: Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder that cannot be prevented, cured or slowed. It affects more than 17...

Published: 7/19/2023 | Inventor(s): Varghese John, Mohammad Parvez Alam, Asa Hatami, Daniel Silverman, Saman Sadeghi

Keywords(s): Cns, Diagnostic Markers & Platforms, Medical Imaging, PET

Category(s): Medical Devices > Medical Imaging > PET

2018-028 PATHWAY-DEPENDENT INHIBITION OF PROTEOPATHIC SEED TRANSMISSION

Pathway-Dependent Inhibition Of Proteopathic Seed TransmissionSUMMARYUCLA researchers in the Department of Neurology have developed a novel approach to stop the propagation of proteopathic diseases, which could be applied to wide range of neurodegenerative disorders including Alzheimer’s disease and Parkinson’s disease.BACKGROUNDProteopathy...

Published: 7/19/2023 | Inventor(s): Neil Garg, Varghese John, Kanagasabai Vadivel, Barbara Jagodzinska, Tina Bilousova

Keywords(s): Cns, Life Science Research Tools, Targets And Assays, Therapeutics & Vaccines

Category(s): Life Science Research Tools, Diagnostic Markers > Targets And Assays, Therapeutics, Therapeutics > CNS and Neurology

2016-305 New 3D-Exoquant Method for the Analysis of Surface Molecules and Quantification of Tissue-Specific Exosomes in Biological Fluids

SUMMARYUCLA researchers in the Department of Neurology have developed a novel high sensitivity exosome and extracellular vesicle disease detection technology for use in the clinical and research setting. BACKGROUNDDetection of surface biomarkers located on extracellular bodies, such as vesicles and exosomes is of great clinical and research significance...

Published: 7/19/2023 | Inventor(s): Varghese John, Patricia Spilman, Jesus Campagna, Peter Heinzelman, Tina Bilousova

Keywords(s): Diagnostic Markers & Platforms, Diagnostic Platform Technologies (E.G. Microfluidics)

Category(s): Diagnostic Markers, Platforms > Diagnostic Platform Technologies

2017-772 ALLOSTERIC BACE INHIBITORS FOR TREATMENT OF ALZHEIMER’S DISEASE

Allosteric BACE Inhibitors For Treatment Of Alzheimer’s DiseaseSUMMARYUCLA researchers from the Department of Neurology have discovered a new class of drug candidates for Alzheimer’s disease. These small molecule compounds can specifically inhibit target enzymes to prevent target protein cleavage through an allosteric mechanism, preventing...

Published: 9/5/2023 | Inventor(s): Varghese John, Barbara Jagodzinska, Patricia Spilman, Jesus Campagna, Kanagasabai Vadivel, Michael Jung

Keywords(s): Cns, Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > CNS and Neurology

2014-864 ApoE4-Targeted Therapeutics that Increase SIRT1

ApoE4-Targeted Theraputics That Increase SIRT1SUMMARYUCLA researchers have identified Alaproclate (A03) as a promising drug candidate to treat Mild Cognition Impairment (MCI) and Alzheimer’s disease (AD) through inhibition of the ApoE4 neurotoxicity.BACKGROUNDAlzheimer’s disease (AD) is a neurodegenerative disease whose cause is largely...

Published: 7/19/2023 | Inventor(s): Michael Jung, Varghese John, Dale Bredesen, Barbara Jagodzinska, Jesus Campagna, Ram Rao, Johnny Pham

Keywords(s):

Category(s): Therapeutics, Therapeutics > CNS and Neurology

1 2